Browse All

Current Filters

CLEAR FILTER x

TITLE

Safety and Efficacy of Frexalimab from the Phase 2 Open-label Extension in Participants with Relapsing Multiple Sclerosis: 2-year Results

Author:Vermersch, Patrick   Granziera, Cristina   Mao-Draayer, Yang   Cutter, Gary   Kalbus, Oleksandr   Staikov, Ivan   Dufek, Michal   Montalban, Xavier   Krieger, Stephen   Saubadu, Stephane   Luo, Xiaodong   Smyth, Brendan   Djukic, Biljana   Truffinet, Philippe   Wallstroem, Erik   Giov,   

Session Name:S3: Multiple Sclerosis: Clinical Trials  

Topic:Multiple Sclerosis  

Program Number:S3.006  

Author Institution:University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France , Lille, France  Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine  Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland  Autoimmunity Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Department of Biostatistics, UAB School of Public Health, Birmingham, AL, USA, Birmingham, AL  Department of Neurology, Dnipro State Medical University, Dnipro, Ukraine, Dnipro, Ukraine  Clinic of Neurology and Sleep Medicine, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria, Sofia, Bulgaria  First Department of Neurology, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic  Multiple Sclerosis Centre of Catalonia, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain , Barcelona, Spain  Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY  Sanofi, Gentilly, France, Gentilly, France  Sanofi, Bridgewater, NJ, USA, Bridgewater, NJ  Sanofi, Cambridge, MA, USA, Cambridge, MA  Queen Mary University of London, London, United Kingdom , London, United Kingdom  

What Can Multidisciplinary Care Do for You? Key Learnings from the Multidisciplinary Multiple Sclerosis Comprehensive and Palliative Care Program

Clinical Features of Children with MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders

Author:Fonseca, Elianet   Olivé-Cirera, Gemma   Chen, Li-Wen   Paredes-Carmona, Fernando   Nuñez Enamorado, Noemí   Boyero Duran, Sabas   Mendibe Bilbao, Maria Del Mar   Visa-Reñé, Nuria   Vazquez-Lopez, Maria   Felipe-Rucián, Ana   Romeu, Gemma   Martinez-Hernandez, Eugenia   M, Blanco   

Session Name:S3: Multiple Sclerosis: Clinical Trials  

Topic:Multiple Sclerosis  

Program Number:S3.008  

Author Institution:Neuroimmunology Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) – Caixa Research Institute, Hospital Clínic de Barcelona, Barcelona, Spain. Pediatric Neuroimmunology Unit, Neurology Department, Sant Joan de Déu Children’s Hospital, ERN-RITA reference center, University of  Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Tainan, Taiwan  Neurology Department, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain. Biobizkaia Health Research Institute. , Bilbao, Spain  Neuroimmunology Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) – CaixaResearch Institute, Hospital Clínic de Barcelona, Barcelona, Spain, Barcelona, Spain  Neuroimmunology Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) – Caixa Research Institute, Hospital Clínic de Barcelona, Barcelona, Spain, Barcelona, Spain  Neuroimmunology Program, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) – Caixa Research Institute, Hospital Clínic de Barcelona, Barcelona, Spain. Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Barcelona, Spain  

Real-world Effectiveness and Predictors of Response to Autologous Haematopoietic Stem Cell Transplantation in MS: The UK Experience in 271 Patients Treated During 2000-2023

7T MRI Study of Cortical and Thalamic Atrophy in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease and Multiple Sclerosis